Related Experiment Video

Updated: Jun 5, 2026

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
06:14

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking

Septimiu Bucurescu1

  • 1Rhoen Klinikum AG Hospital, Bad Neustadt ad Saale, Germany. s_bucurescu@yahoo.com

Acta Pharmaceutica (Zagreb, Croatia)
|December 21, 2010
PubMed

Insights

Future cancer treatments involve molecular cures. Herpes simplex virus type 1 glycoproteins E and I show potential in adjuvant cancer therapy by enhancing oncolytic virus efficacy against cancer cells.

Area of Science:

  • Oncology
  • Virology
  • Immunotherapy

Background:

  • Future cancer therapies aim for molecular cures targeting carcinogenesis.
  • Oncolytic viruses are a promising strategy for destroying cancer cells.
  • Antibody-mediated neutralization can limit the effectiveness of oncolytic viruses in vivo.

Purpose of the Study:

  • To investigate the potential of Herpes simplex virus type 1 (HSV-1) glycoproteins E and I.
  • To evaluate if these glycoproteins can block antibody-mediated neutralization of oncolytic viruses.
  • To determine if HSV-1 glycoproteins can improve the in vivo efficacy of oncolytic viruses in cancer treatment.

Main Methods:

  • The study focuses on the molecular mechanisms of HSV-1 glycoproteins E and I.
  • It explores their role in evading the immune system's antibody response.
  • The research investigates the application of these glycoproteins in combination with oncolytic viruses.

Main Results:

  • Herpes simplex virus type 1 glycoproteins E and I can block antibody-mediated neutralization.
  • This blockade enhances the ability of oncolytic viruses to infect and destroy cancer cells.
  • The use of these glycoproteins as an adjuvant therapy improves oncolytic virus effectiveness in vivo.

Conclusions:

  • HSV-1 glycoproteins E and I hold promise for improving oncolytic virotherapy.
  • Targeting molecular changes with therapies like these represents a future direction in cancer treatment.
  • Adjuvant therapy with HSV-1 glycoproteins could enhance oncolytic virus-mediated cancer cell killing.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Concept Videos

Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Herpes01:28

Herpes

Herpes simplex type 1 (HSV‑1) is a widespread pathogen responsible for orolabial lesions. It is an enveloped, double-stranded DNA (dsDNA) virus belonging to the family Herpesviridae. Once the virus infects a host cell, its double‑stranded DNA genome is delivered into the nucleus, where a coordinated cascade of immediate‑early, early, and late gene expression directs viral DNA replication, structural protein synthesis, and virion assembly. After primary infection of epithelial cells, HSV-1...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...